產(chǎn)品名稱：Rheumatoid Factor Screen ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號(hào)：DE7660 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說(shuō)明： Special remarks: NAME AND INTENDED USE Rheumatoid Factor Screen is an indirect solid phase enzyme immunoassay (ELISA) for the simultaneous quantitative measurement of IgG, IgM and IgA class rheumatoid factor antibodies in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of rheumatoid arthritis (RA). SUMMARY AND EXPLANATION OF THE TEST The presence of IgM Rheumatoid Factor (RF) in the serum is the sole serological indicator included in the ACR list of criteria for the diagnosis of RA. RFs are a subset of antiglobulins directed against the Fc region of IgG. We do not include in this definition antibodies to the IgG Fab region and pepsin agglutinators, directed against neoantigens on IgG exposed by pepsin cleavage. It is claimed that the majority of antiglobulin activity in normal serum is Fab-specific, whereas antiglobulin from RA patients is mostly Fc-specific. RFs are present in the serum of 75-80% of patients with RA at some time during the disease course. However, RFs are also found in the serum of patients with infectious and autoimmune diseases, hyperglobulinemias, B-cell lymphoproliferative disorders and in the aged population. This suggests that RF may be a finding associated with B-cell hyperactivity. Rheumatoid Factors which have been found among the IgM, IgG and IgA classes of immunoglobulins, reacting only with xenogeneic Fc are not autoantibodies and are unlikely to be of pathological significance. However, RFs can bind IgG from many species, including autologous IgG, when immobilized on surfaces. Autologous binding is of higher affinity than xenogeneic binding. The here presented test systems for the deter-mination of rheumatoid factors uses only human Fc-fragments as coated antigen. It is generally considered that high titer RFs are associated with more severe disease and the presence of extra-articular features and rheumatoid nodules. This conclusion may depend on the disease duration. Serum IgM RF may precede the onset of RA by several years. A high titer of RF in non-RA individuals is associated with increased risk of developing RA. In the first 2 years of RA (early RA), serum levels of IgM, IgG and IgA RF do not correlate with disease activity. Serum IgG and IgA RF in these years are prognostic of erosive joint disease. In established RA, high titer serum IgM RF correlates with the presence of articular disease and nodules but not with systemic disease activity. The presence of either IgG or IgA RF in patients with long-standing RA may be a good prognostic indicator of systemic manifestations. IgG and IgM RF are associated with extra-articular RA including rheumatoid vasculitis and nodules. The presence of IgM RF - containing immune complexes with bound complement (C1q) - is also associated with extra-articular RA. 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國(guó)內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個(gè)國(guó)家近五十萬(wàn)種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長(zhǎng)和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對(duì)生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號(hào)
